Title: Erythropoietin and ischemic conditioning – why two good things may be bad
Abstract: Acta PaediatricaVolume 96, Issue 6 p. 787-789 Erythropoietin and ischemic conditioning – why two good things may be bad Christoph Bührer, Christoph Bührer Department of Neonatology, Basel University Children's Hospital, Basel, SwitzerlandSearch for more papers by this authorUrsula Felderhoff-Mueser, Ursula Felderhoff-Mueser Department of Neonatology, Charité University Medical Center, Berlin, GermanySearch for more papers by this authorSven Wellmann, Sven Wellmann Department of Neonatology, Basel University Children's Hospital, Basel, SwitzerlandSearch for more papers by this author Christoph Bührer, Christoph Bührer Department of Neonatology, Basel University Children's Hospital, Basel, SwitzerlandSearch for more papers by this authorUrsula Felderhoff-Mueser, Ursula Felderhoff-Mueser Department of Neonatology, Charité University Medical Center, Berlin, GermanySearch for more papers by this authorSven Wellmann, Sven Wellmann Department of Neonatology, Basel University Children's Hospital, Basel, SwitzerlandSearch for more papers by this author First published: 24 May 2007 https://doi.org/10.1111/j.1651-2227.2007.00335.xCitations: 10 Correspondence Christoph Bührer, Universitäts-Kinderspital beider Basel (UKBB), CH-4005 Basel, Switzerland. Tel: +41-61-2659565 | Fax: +41-61-265968 | Email: [email protected] Articles published in the series A Different View are edited by Alan Leviton ([email protected]) Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Ohlsson A, Aher SM. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2006; 3: CD004863. 2 Melnikova I. Anaemia therapies. Nat Rev Drug Discov 2006; 5: 627– 628. 3 Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002; 8: 495– 505. 4 Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 2004; 44: 866– 876. 5 Cotter DJ, Stefanik K, Zhang Y, Thamer M, Scharfstein D, Kaufman J. Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients. J Clin Epidemiol 2004; 57: 1086– 1095. 6 Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003; 4: 459– 460. 7 Henke M, Laszig R, Rube C, Schäfer U, Haase KD, Schilcher B et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362: 1255– 1260. 8 Gidday JM, Fitzgibbons JC, Shah AR, Park TS. Neuroprotection from ischemic brain injury by hypoxic preconditioning in the neonatal rat. Neurosci Lett 1994; 168: 221– 224. 9 Vannucci RC, Towfighi J, Vannucci SJ. Hypoxic preconditioning and hypoxic-ischemic brain damage in the immature rat: pathologic and metabolic correlates. J Neurochem 1998; 71: 1215– 1220. 10 Ruscher K, Freyer D, Karsch M, Isaev N, Megow D, Sawitzki B et al. Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro model. J Neurosci 2002; 22: 10291– 10301. 11 Bernaudin M, Nedelec AS, Divoux D, MacKenzie ET, Petit E, Schumann-Bard P. Normobaric hypoxia induces tolerance to focal permanent cerebral ischemia in association with an increased expression of hypoxia-inducible factor-1 and its target genes, erythropoietin and VEGF, in the adult mouse brain. J Cereb Blood Flow Metab 2002; 22: 393– 403. 12 Prass K, Scharff A, Ruscher K, Löwl D, Muselmann C, Victorov I et al. Hypoxia-induced stroke tolerance in the mouse is mediated by erythropoietin. Stroke 2003; 34: 1981– 1986. 13 Malhotra S, Savitz SI, Ocava L, Rosenbaum DM. Ischemic preconditioning is mediated by erythropoietin through PI-3 kinase signaling in an animal model of transient ischemic attack. J Neurosci Res 2006; 83: 19– 27. 14 Ran R, Xu H, Lu A, Bernaudin M, Sharp FR. Hypoxia preconditioning in the brain. Dev Neurosci 2005; 27: 87– 92. 15 Liu J, Narasimhan P, Yu F, Chan PH. Neuroprotection by hypoxic preconditioning involves oxidative stress-mediated expression of hypoxia-inducible factor and erythropoietin. Stroke 2005; 36: 1264– 1269. 16 Weber A, Dzietko M, Berns M, Felderhoff-Mueser U, Heinemann U, Maier RF et al. Neuronal damage after moderate hypoxia and erythropoietin. Neurobiol Dis 2005; 20: 594– 600. 17 Dzietko M, Felderhoff-Mueser U, Sifringer M, Krutz B, Bittigau P, Thor F et al. Erythropoietin protects the developing brain against N-methyl-D-aspartate receptor antagonist neurotoxicity. Neurobiol Dis 2004; 15: 177– 187. 18 Beleslin-Cokic BB, Cokic VP, Yu X, Weksler BB, Schechter AN, Noguchi CT. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood 2004; 104: 2073– 2080. 19 Li W, Maeda Y, Yuan RR, Elkabes S, Cook S, Dowling P. Beneficial effect of erythropoietin on experimental allergic encephalomyelitis. Ann Neurol 2004; 56: 767– 777. 20 Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci U S A 1998; 95: 4635– 4640. 21 Ehrenreich H, Hasselblatt M, Knerlich F, Von Ahsen N, Jacob S, Sperling S et al. A hematopoietic growth factor, thrombopoietin, has a proapoptotic role in the brain. Proc Natl Acad Sci U S A 2005; 102: 862– 867. 22 Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A 2004; 101: 14907– 14912. 23 Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 2005; 6: 484– 494. 24 Banks WA, Jumbe NL, Farrell CL, Niehoff ML, Heatherington AC. Passage of erythropoietic agents across the blood-brain barrier: a comparison of human and murine erythropoietin and the analog darbepoetin alfa. Eur J Pharmacol 2004; 505: 93– 101. 25 Juul SE, Stallings SA, Christensen RD. Erythropoietin in the cerebrospinal fluid of neonates who sustained CNS injury. Pediatr Res 1999; 46: 543– 547. 26 Juul SE, McPherson RJ, Farrell FX, Jolliffe L, Ness DJ, Gleason CA. Erytropoietin concentrations in cerebrospinal fluid of nonhuman primates and fetal sheep following high-dose recombinant erythropoietin. Biol Neonate 2004; 85: 138– 144. 27 Xenocostas A, Cheung WK, Farrell F, Zakszewski C, Kelley M, Lutynski A et al. The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin. Eur J Clin Pharmacol 2005; 61: 189– 195. 28 Barnard K, Herold R, Siemes H, Siegert M. Quantification of cerebrospinal fluid proteins in children by high-resolution agarose gel electrophoresis. J Child Neurol 1998; 13: 51– 58. 29 Plateel M, Teissier E, Cecchelli R. Hypoxia dramatically increases the nonspecific transport of blood-borne proteins to the brain. J Neurochem 1997; 68: 874– 877. Citing Literature Volume96, Issue6June 2007Pages 787-789 ReferencesRelatedInformation
Publication Year: 2007
Publication Date: 2007-05-24
Language: en
Type: article
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 12
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot